The effects of laser assisted disinfection treatments on peri-implant disease

The effect of photodynamic therapy with indocyanine green photosensitizer on nonsurgical management of peri-implant diseases and the periodontopathic bacteria

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201610211248N4

Enrollment

Registered

2017-02-10

Start date

2016-10-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peri-implant disease. Presence of tooth-root and mandibular implants, Gingivitis and periodontal diseases

Interventions

Intervention 1: The affected sites will be debrided mechanically using ultrasonic devices under local anesthesia. Consequently, a photosensitizer agent ( Indocyanine green) will be inserted into peri-

Treatment - Other

The affected sites will be debrided mechanically using ultrasonic devices under local anesthesia. Consequently, a photosensitizer agent ( Indocyanine green) will be inserted into peri-implant pockets

The affected sites will be debrided mechanically using ultrasonic devices under local anesthesia. The patient will be instructed to avoid intake of any food/beverages for 2 hours.

Eligibility

Sex/Gender

All

Age

18 Years to 120 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: At least 18 years old; Presence of at least ONE implant with at least ONE year in function ;Presence of Peri- implant disease ( severe peri-implant mucositis or mild peri- implantitis which is placed in ISI class II, III and IVaccording to theKadkhodazade and Amid classification with a positive bleeding on probing, probing depth of 4 mm or more,no soft tissue loss with or without bone loss of 2mm or less in periapical radiographs) Exclusion Criteria:Using antibiotic from 3 months prior to study ; Using NSAIDS and/or corticosteroids at the recent 3 months, ;Presence of any history of any treatment for peri- implant disease during last 3 months ;Being a current and/or former smokers , drug or alcohol abuser ; Using Bisphosphonates, Cyclosporine, Coumadin, Warfarin and Heparin ;Pregnancy and lactation; Presence of an active periodontal disease after therapy ;Presence of poorly controlled diabetes and other debilitating diseases ;Refraining to sign the consent form

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Bleeding on Probing. Timepoint: 2 weeks, 1 mounths,3 months. Method of measurement: Clinical Examination.	—

Secondary

Measure	Time frame
Probing depth. Timepoint: 2weeks,1month and 3 months. Method of measurement: clinical and laboratory assessment.;Clinical attachment level. Timepoint: 2weeks,1month and 3 months. Method of measurement: clinical examination.;Pain on Probing. Timepoint: 2weeks,1month and 3 months. Method of measurement: clinical examination.;Common microorganisms. Timepoint: 2weeks,1month and 3 months. Method of measurement: laboratory assessment.	—

Measure

Time frame

Probing depth. Timepoint: 2weeks,1month and 3 months. Method of measurement: clinical and laboratory assessment.;Clinical attachment level. Timepoint: 2weeks,1month and 3 months. Method of measurement: clinical examination.;Pain on Probing. Timepoint: 2weeks,1month and 3 months. Method of measurement: clinical examination.;Common microorganisms. Timepoint: 2weeks,1month and 3 months. Method of measurement: laboratory assessment.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Reza Pourabbas

Tabriz University of Medical Sciences

rpourabbas@yahoo.com+98 41 3328 1190

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026